ArticleInternational journal of clinical pharmacy2025

Comparative risks of inflammatory bowel disease in patients with type 2 diabetes mellitus treated with SGLT-2 inhibitors versus DPP-4 inhibitors: a real-world nationwide cohort study.

Ya-Ju Yu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.